Under the terms of the agreement, Twist Biopharma, a division of Twist Bioscience, will leverage its unique "library of libraries" for biologics discovery and its proprietary discovery capabilities to discover novel GPCR target-specific antibodies for Kyowa Kirin, the company said in a statement.

Twist received an upfront payment upon signing, while Kyowa Kirin retains an option to obtain development and commercial rights to any antibodies resulting from the agreement, company officials said.

Financial details of the agreement were not disclosed.

Twist Bioscience inks agreements for antibody therapeutic discovery
Twist Bioscience said that its Twist Biopharma division has signed licensing deals with Serotiny and Applied StemCell aimed at discovering new antibody...

Twist to offer RNA control for U.K. strain of SARS-CoV-2
Twist Bioscience plans to offer a new synthetic RNA control that includes the new variant of SARS-CoV-2 circulating in the U.K. and South Africa.

Twist offers new gene fragments to the synthetic biology market
Twist Bioscience has launched its new clonal-ready gene fragments. The gene fragments, with and without adapters, can be used to rapidly build constructs...

Twist Bioscience touts positive preclinical data for SARS-CoV-2 antibodies
Twist Bioscience has touted preclinical results for three of its proprietary antibodies against the novel coronavirus S1 subunit protein.

Firms partner with Microsoft to advance DNA data storage
Twist Bioscience, Illumina, and Western Digital have formed an alliance with Microsoft to advance the field of DNA data storage.